Memorial Sloan Kettering Cancer Center Issues Statement on Third Quarter 2026 Financial Results

Memorial Sloan Kettering Cancer Center (MSK) today issued the following statement regarding its financial results for the first three quarters of 2026: 

MSK reported an excess of operating revenues over expenses of $339.1 million and an operating cash flow margin of 8.9% for the first nine months of 2026. These results reflect higher patient activity levels, supported by ongoing improvements in patient access and operating efficiencies realized through the Epic electronic health record (EHR) system.

Through the first three quarters of 2026, operating revenues increased 12.1% compared with the same period ended September 30, 2025. Revenue increases were driven primarily by higher patient revenues. When excluding one-time revenue items, including COVID Relief funding and settlement payments, operating revenues increased 11.1%.

Operating expenses increased 3.8% compared with the prior-year period. Excluding incremental costs recorded in the prior-year period associated with the Epic EHR system implementation, operating expenses increased 6.6%. The increase was driven primarily by higher personnel costs and pharmaceutical expenses, consistent with increased patient activity levels and industrywide increases in drug prices.

MSK remains focused on advancing a long-term financial strategy centered on expanding patient access, strengthening operational discipline, and supporting the Institution’s mission-driven growth amid continued cost pressures across the healthcare sector.

For more information, please see instructions to access our financial disclosure report available at https://www.dacbond.com/ or https://www.mskcc.org/public-notices/financial-information.